Poisoned in the Womb: When Medicine's Mistakes Echo Through Generations - Jill Escher (#19)
26 June 2025
With Jill Escher
Global
Jill Escher, president of the National Council on Severe Autism, traces how synthetic steroid hormones administered to pregnant women in the mid-twentieth century may have permanently altered the neurodevelopmental trajectories of their children and grandchildren. The episode draws a documented thread between prenatal hormone exposure, rising autism rates and the surge in gender dysphoria — a connection the Cass Review's own data hinted at in noting the high prevalence of neurodivergence among young people presenting to gender clinics. The conversation raises urgent questions about medical accountability and the institutional silence that allows historical mistakes to go unacknowledged.
Jill Escher is president of the National Council on Severe Autism and the mother of two profoundly autistic sons. Her search for an explanation led her to medical records showing her mother had received regular injections of synthetic steroid hormones during pregnancy in the 1960s. That discovery set her on a longer investigation into how pharmaceutical interventions during gestation can alter gene expression across generations — a field known as transgenerational epigenetics. The episode examines one of the twentieth century's most consequential pharmaceutical disasters. Diethylstilbestrol, or DES, was a synthetic oestrogen prescribed to pregnant women across the United States, the United Kingdom and beyond from the 1940s, marketed as a way to prevent miscarriage. It was eventually withdrawn after daughters of women who took it developed elevated rates of a rare vaginal cancer and serious reproductive abnormalities. Escher's own mother received different synthetic steroid hormones, and the conversation extends to a broader class of prenatal pharmaceutical exposures whose long-term neurological consequences remain poorly understood. The episode's central argument — that rising autism rates and the sharp increase in gender dysphoria may share a common upstream cause in prenatal hormonal disruption — carries particular weight in the UK context. The Cass Review, published in April 2024, documented that a substantial proportion of young people referred to NHS gender clinics had autism or other neurodevelopmental conditions. Cass did not resolve why the overlap exists, but identified it as one of the most clinically significant features of the referral population. Escher's framework, linking prenatal hormone exposure to both neurodevelopmental and gender-related difficulties, offers a line of inquiry that formal research has not yet adequately pursued. Escher extends the argument beyond the first generation. Research into epigenetic inheritance suggests that environmental exposures can alter how genes are expressed without modifying the underlying DNA sequence, and that those alterations can be transmitted to subsequent generations. If mid-century synthetic hormone prescriptions reshaped gene expression in the women who received them, their children and grandchildren may be living with neurological consequences that have never been formally attributed to a pharmaceutical cause. Given the scale of prenatal hormone prescribing across the twentieth century, the potential population-level effects are not trivial. The episode is equally a challenge to institutional inertia. Escher notes that some anti-miscarriage drugs remained in clinical use until 2023, long after questions about their safety had been raised. The pattern — an intervention promoted as safe, adopted widely, and only belatedly acknowledged as harmful — is one that anyone following the debate over puberty blockers and cross-sex hormones for adolescents will recognise. The calls she makes for independent research, institutional honesty about past errors, and the willingness to follow evidence wherever it leads map directly onto demands that have shaped the UK debate since the Cass Review forced a reckoning with the evidence base for paediatric gender care.
